Blogs and updates

A practical guide for pharmaceutical sponsors and biotech clinical operations leaders evaluating phase II and III trial service partners for oncology, complex site activation, and quality management programs. Phase II and III trials represent the highest stakes stage of the clinical...

A definitive guide for pharmaceutical sponsors and CRO clinical operations leaders on building sponsor recruitment support infrastructure through community clinic partnerships, embedded research models, and diverse patient enrollment strategies. Sponsor recruitment support is one of the most consequential investments a clinical...

A practical guide for pharmaceutical sponsors and CRO clinical operations leaders evaluating clinical trial recruitment partners that operate through community clinics, embedded care settings, and diverse enrollment networks. Reaching enrollment targets in clinical trials is one of the most persistent challenges...

When a clinical trial fails to enroll on time, the problem rarely starts with recruitment. It starts with the distance between where patients receive care and where research happens. Traditional site models ask patients to travel to separate facilities, follow separate...

Few problems cost sponsors more time and money than patient recruitment bottlenecks in Phase II and III trials. A study that cannot enroll on schedule delays first patient in, pushes back database lock, and threatens the entire development timeline. For clinical...

Recruitment and retention remain the two hardest problems in clinical research, and they are getting harder. For pharmaceutical sponsors and CRO clinical operations leaders running Phase II and III studies, weak clinical trial patient recruitment delays timelines, inflates costs, and produces...

In oncology, the gap between a signed contract and a fully activated site is where timelines quietly slip away. For pharmaceutical sponsors, CRO leaders, and biotech clinical operations teams running Phase II and III cancer studies, oncology site activation is one...

Choosing the right oncology clinical trial site can determine whether a study enrolls on time, retains patients, and produces clean data that holds up to regulatory scrutiny. For pharmaceutical sponsors and biotech clinical operations leaders, the decision goes far beyond geography....

Phase II and III trials are where sponsors commit the most time, capital, and scientific reputation, yet they are also where participant loss does the most damage. A study that enrolls slowly or bleeds participants midway through dosing can push timelines...

Retention is where many Phase II and III studies quietly lose ground, and it almost always traces back to how the study began. Strong patient retention in clinical trials depends less on chasing dropouts and more on building continuity from the...

The way sponsors design enrollment is shifting, and embedded research in clinical trials sits at the center of that change. Rather than asking patients to travel to dedicated research facilities, this approach folds studies into the everyday practices where people already...

Biotech trial recruitment has become the deciding factor in whether a study finishes on time or stalls in startup. For sponsors and clinical operations leaders, the question is no longer whether to outsource recruitment but which model actually reaches the patients...